OncoLens is a cutting-edge, AI-enabled digital healthcare platform designed to revolutionize cancer care by leveraging both structured and unstructured clinical data from EMRs, labs, and pathology systems. The platform integrates seamlessly into existing clinical workflows to provide timely, precise interventions and actionable insights, significantly improving patient outcomes and operational efficiency.
Key Benefits and Capabilities:
- Multidisciplinary Care Coordination: The platform centralizes patient data (clinical, lab, genomic, imaging) into a singular, comprehensive view, enabling coordinated treatment planning across a network of providers.
- Virtual Tumor Board (OncoLens Conference): It automates the tumor board process, including case intake, data collection (pathology, radiology), and accreditation reporting (CoC, NAPBC, NAPRC). This automation can reduce preparation time by over 90%.
- AI-Powered Patient Identification (Patient ID): OncoLens uses AI, Natural Language Processing (NLP), and Large Language Models (LLMs) to screen structured and unstructured EHR data, identifying patients who are eligible for clinical trials, targeted therapies, CAR-T, and other advanced treatments in real-time.
- Clinical Decision Support: The platform delivers evidence-based protocols, clinical trial opportunities, and customized pathways directly into the workflow, supporting confident clinical decision-making.
- Data Analytics & RWE: OncoLens Analytics provides real-time executive dashboards, automated registry reports, and patient journey reports, enabling cancer centers and life science companies to generate real-world evidence (RWE) and drive quality improvement initiatives.
- Molecular Tumor Board Support: It assists in the clearer visualization and assessment of genomic data, integrating NGS test results and providing links to actionable therapies based on individual tumor biology.
OncoLens serves a wide range of organizations, including NCI-Designated Cancer Centers, Academic Institutions, Integrated Delivery Networks (IDNs), Community Cancer Centers, and Life Science companies, with an extensive network covering over 5,000,000 oncology patients.